JP Morgan Chase
IBBQ icon

JP Morgan Chase’s Invesco NASDAQ Biotechnology ETF IBBQ Stock Holding History

JP Morgan Chase’s Portfolio IBBQ Stock Details IBBQ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-238,777
Closed -$6.11M – 6785
2021
Q3 		$6.11M Sell
238,777
-161,220
-40% -$4.25M ﹤0.01% 2873
2021
Q2 		$10.4M Buy
+399,997
New +$10.2M ﹤0.01% 2402

Other funds holding IBBQ

Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
AF
Apexium Financial Dallas, Texas $2.06B AUM 15.96% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
AIP
Ahrens Investment Partners Lafayette, Louisiana $202M AUM 3.91% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase's IBBQ Position: Q4 2021 in Review

JP Morgan Chase sold out of Invesco NASDAQ Biotechnology ETF (IBBQ) in Q4 2021, closing a stake of 238,777 shares — an estimated $6.11M sold.

JP Morgan Chase first reported a position in IBBQ in Q2 2021 and held it in 2 quarters. The position peaked at $10.4M in Q2 2021. 9 funds tracked by Wall St. Rank hold IBBQ as of Q4 2021.

  • JP Morgan Chase reported no remaining Invesco NASDAQ Biotechnology ETF position as of Q4 2021 after selling out during the quarter.
  • JP Morgan Chase sold 238,777 Invesco NASDAQ Biotechnology ETF shares in Q4 2021, an estimated $6.11M.
  • JP Morgan Chase first reported a position in Invesco NASDAQ Biotechnology ETF in Q2 2021 and held it in 2 quarters.
  • JP Morgan Chase's Invesco NASDAQ Biotechnology ETF position peaked at $10.4M in Q2 2021.
  • 9 funds tracked by Wall St. Rank held Invesco NASDAQ Biotechnology ETF as of Q4 2021.

Based on JP Morgan Chase's 13F filing for Q4 2021, filed 10 Feb 2022.